Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Xavier MontalbanKarolina Piasecka-StryczynskaJens KuhlePascal BenkertDouglas Lorne ArnoldMartin S WeberAndrea SeitzingerHans GuehringJamie ShawDavorka TomicYann HyvertDanielle E HarlowMartin DyroffJerry S WolinskyPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
Long-term evobrutinib treatment was well tolerated and associated with a sustained low level of disease activity. Evobrutinib was present in CSF at concentrations similar to plasma.